Another gold compound used to treat RA, auranofin (ANF), is reported to block the interaction of PKCι with Par6 more potently than ATM (Parker et al., 2014) and phase I/II trials are ongoing to investigate the effect of ANF in combination with an mTOR inhibitor in lung cancer (NCT01737502). Here, PRKCA is linked to lung carcinoma.